Abstract
In order to explore structure-activity relationship (SAR) associated with xanthone framework, a series of prenylated xanthone derivatives 2-9 was synthesized from the key building block 1,3,6,8-tetrahydroxyxanthone 1 and evaluated for their in vitro growth inhibitory activities against HeLa and MDA-MB-231 human cancer cell lines. The in vitro evidence indicated that the inhibitory activity was significantly influenced by the position and number of linked group on the xanthone skeleton, and the presence of chroman-4-one moiety in the xanthone scaffold was found to be critically important for strong cytotoxic activity. The novel 2H-xanthene-3,9-dione analogues 3 and 4 were reported to elicit potent activities comparable to those of standard drugs doxorubicin and cisplatin. This preliminary investigation has highlighted the therapeutic potential of 2H-xanthene-3,9-dione derivatives to be exploitable as lead compound for the development of potent HeLa and MDA-MB-231 cancer cell inhibitors.
Keywords: Cytotoxicity, 2H-xanthene-3,9-dione scaffold, 2H-xanthene-3,6,9(7H)-trione scaffold, Inhibitory activity, Synthesis, Xanthone derivatives, SAR, Xanthone, HeLa, MDA-MB-231, Cancer, prenylated, anti-inflammatory, 1,3-dihydroxyxanthone, phloroglucinol, acylphloroglucinols
Letters in Drug Design & Discovery
Title: Synthesis and SAR Study of Prenylated Xanthone Analogues as HeLa and MDA-MB-231 Cancer Cell Inhibitors
Volume: 8 Issue: 6
Author(s): Chan Kiang Lim, Lai-Yeng Tho, Cheng Hoe Lim, Yang Mooi Lim, Syed Adnan Ali Shah and Jean-Frederic Faizal Weber
Affiliation:
Keywords: Cytotoxicity, 2H-xanthene-3,9-dione scaffold, 2H-xanthene-3,6,9(7H)-trione scaffold, Inhibitory activity, Synthesis, Xanthone derivatives, SAR, Xanthone, HeLa, MDA-MB-231, Cancer, prenylated, anti-inflammatory, 1,3-dihydroxyxanthone, phloroglucinol, acylphloroglucinols
Abstract: In order to explore structure-activity relationship (SAR) associated with xanthone framework, a series of prenylated xanthone derivatives 2-9 was synthesized from the key building block 1,3,6,8-tetrahydroxyxanthone 1 and evaluated for their in vitro growth inhibitory activities against HeLa and MDA-MB-231 human cancer cell lines. The in vitro evidence indicated that the inhibitory activity was significantly influenced by the position and number of linked group on the xanthone skeleton, and the presence of chroman-4-one moiety in the xanthone scaffold was found to be critically important for strong cytotoxic activity. The novel 2H-xanthene-3,9-dione analogues 3 and 4 were reported to elicit potent activities comparable to those of standard drugs doxorubicin and cisplatin. This preliminary investigation has highlighted the therapeutic potential of 2H-xanthene-3,9-dione derivatives to be exploitable as lead compound for the development of potent HeLa and MDA-MB-231 cancer cell inhibitors.
Export Options
About this article
Cite this article as:
Kiang Lim Chan, Tho Lai-Yeng, Hoe Lim Cheng, Mooi Lim Yang, Adnan Ali Shah Syed and Faizal Weber Jean-Frederic, Synthesis and SAR Study of Prenylated Xanthone Analogues as HeLa and MDA-MB-231 Cancer Cell Inhibitors, Letters in Drug Design & Discovery 2011; 8 (6) . https://dx.doi.org/10.2174/157018011795906820
DOI https://dx.doi.org/10.2174/157018011795906820 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibition of V-ATPase and Carbonic Anhydrases as Interference Strategy with Tumor Acidification Processes
Current Pharmaceutical Design The Non-Canonical IκB Kinases IKKε and TBK1 as Potential Targets for the Development of Novel Therapeutic Drugs
Current Molecular Medicine Pediatric Immune Dysfunction and Health Risks Following Early-Life Immune Insult
Current Pediatric Reviews Cancer-associated Autoantibodies as Biomarkers for Early Detection and Prognosis is Cancer: An Update
Current Cancer Therapy Reviews Beyond Cox-Inhibition: ‘Side-Effects’ of Ibuprofen on Neoplastic Development and Progression
Current Pharmaceutical Design P-Glycoprotein and Breast Cancer Resistance Protein Affect Disposition of Tandutinib, A Tyrosine Kinase Inhibitor
Drug Metabolism Letters Peptides for Tumour Therapy and Diagnosis: Current Status and Future Directions
Current Medicinal Chemistry An Overview of the α4β1 Integrin and the Potential Therapeutic Role of its Antagonists
Current Medicinal Chemistry Computed Tomographic Evaluation of Colonic Diverticulum Complications
Current Medical Imaging Thyroid Hormones Crosstalk with Growth Factors: Old Facts and New Hypotheses
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Non-Coding RNA in Brain Development and Disorder
Current Medicinal Chemistry Pulmonary Infections in the Era of Biological Agents
Current Respiratory Medicine Reviews Resveratrol and Neurodegenerative Diseases: Activation of SIRT1 as the Potential Pathway towards Neuroprotection
Current Neurovascular Research Molecular Chaperone Hsp90 as a Target for Oxidant-Based Anticancer Therapies
Current Medicinal Chemistry Polypharmacology of Approved Anticancer Drugs
Current Drug Targets Treatment of Pancreatic Cancer with Pharmacological Ascorbate
Current Pharmaceutical Biotechnology Pharmacogenetics of Non-small Cell Lung Cancer (NSCLC): Time to "Work it Out"?
Current Pharmaceutical Design Apoptosis Signaling Pathways in Anticancer Therapy
Current Cancer Therapy Reviews MicroRNAs: The New Challenge for Traumatic Brain Injury Diagnosis
Current Neuropharmacology Modulation of MicroRNAs by <i>Euphorbia Microsciadia</i> Boiss in MDA-MB-231 Cell Line: New Possibilities in Breast Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery